Page last updated: 2024-11-13
lys-pro-arg-arg-pro-tyr-vip(7-28)
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
(VIP-neurotensin) hybrid antagonist: contains fractions of VIP peptide & neurotensin; 28 amino acid sequence given in first source; consists of an N-terminal sequence from neurotensin and the 22 C-terminal amino acids of vasoactive intestinal peptide (VIP); inhibits VIP receptor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 102602038 |
MeSH ID | M0188922 |
Synonyms (13)
Synonym |
---|
125093-93-8 |
(lys(1)-pro(2,5)-arg(3,4)-tyr(6))vip(7-28) |
viphyb |
vip-ne hybrid antag |
vasoactive intestinal octacosapeptide (pig), 1-l-lysine-2-l-proline-3-l-arginine-4-l-arginine-5-l-proline-6-l-tyrosine- |
neurotensin(6-11)vip(7-28) |
lys-pro-arg-arg-pro-tyr-vip(7-28) |
(vip-neurotensin) hybrid antagonist |
lysyl-prolyl-arginyl-arginyl-prolyl-tyrosyl-vip(7-28) |
vip antagonist |
h-lys-pro-arg-arg-pro-tyr-thr-asp-asn-tyr-thr-arg-leu-arg-lys-gln-met-ala-val-lys-lys-tyr-leu-asn-ser-ile-leu-asn-nh2 |
mfcd00080365 |
h-lys-pro-arg-arg-pro-tyr-thr-asp-asn-tyr-thr-arg-leu-arg-lys-gln-met-ala-val-lys-lys-tyr-leu-asn-se |
Research Excerpts
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" In contrast, PHI was an effective stimulant in doses up to 15 nmol/rat but had no effect on either ACTH or CORT at a dose of 30 nmol/rat thus yielding a bell-shaped dose-response curve." | ( VIP antagonist demonstrates differences in VIP- and PHI-mediated stimulation and inhibition of ACTH and corticosterone secretion in rats. Alexander, LD; Sander, LD, 1995) | 0.29 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (16)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 6 (37.50) | 18.2507 |
2000's | 4 (25.00) | 29.6817 |
2010's | 6 (37.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.69
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.69) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 17 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |